Clinical Trial Update: Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring treatment of peanut allergy with Xolair (omalizumab) in combination with oral immunotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Caroline Nilsson | Conditions: Peanut Allergy | Phase 2 | Status: UNKNOWN